APLT - Applied Therapeutics Inc Stock Price, Fair Value and News

$9.24-0.19 (-2.01%)

Delayed as of 21 Nov 2024, 10:02 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

APLT Price Action

Last 7 days

5.7%

Last 30 days

4.9%

Last 90 days

68.4%

Trailing 12 Months

376.3%

APLT RSI Chart

APLT Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-5.86

Price/Sales (Trailing)

113.41

Price/Free Cashflow

-13.41

APLT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

APLT Fundamentals

APLT Revenue

Revenue (TTM)

10.0M

Rev. Growth (Qtr)

-15.28%

APLT Earnings

Earnings (TTM)

-187.3M

Earnings Growth (Yr)

-61.89%

Earnings Growth (Qtr)

-2.5K%

APLT Profitability

Return on Equity

-3.2K%

Return on Assets

-175.77%

Free Cashflow Yield

-7.46%

APLT Investor Care

Shares Dilution (1Y)

50.66%

Diluted EPS (TTM)

-1.64

APLT Alerts

JANUS HENDERSON GROUP PLC reported owning 9.2% of APLT [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	10.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Applied Therapeutics Inc

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

CEO	Dr. Shoshana Shendelman Ph.D.
WEBSITE	appliedtherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	22

Applied Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Applied Therapeutics Inc? What does APLT stand for in stocks?

APLT is the stock ticker symbol of Applied Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Applied Therapeutics Inc (APLT)?

As of Wed Nov 20 2024, market cap of Applied Therapeutics Inc is 1.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APLT stock?

You can check APLT's fair value in chart for subscribers.

Is Applied Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APLT is over valued or under valued. Whether Applied Therapeutics Inc is cheap or expensive depends on the assumptions which impact Applied Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APLT.

What is Applied Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, APLT's PE ratio (Price to Earnings) is -5.86 and Price to Sales (PS) ratio is 113.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLT PE ratio will change depending on the future growth rate expectations of investors.